^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    DYNLT1 (Dynein Light Chain Tctex-Type 1)

    i
    Other names: DYNLT1, Dynein Light Chain Tctex-Type 1, TCTEX1, Tctex-1, TCTEL1, T-Complex-Associated-Testis-Expressed 1-Like 1, T-Complex Testis-Specific Protein 1 Homolog, Protein CW-1, TCTEX-1, CW-1
    Associations

    News

    Trials
    1m
    Integrative multi-omics analysis reveals the potential mechanisms of innate immunity in ovarian cancer tumorigenesis and immunotherapy responses. (PubMed, J Ovarian Res)
    Molecular docking and molecular dynamics simulations suggest that the Chinese herbal monomer Mulberrofuran K may be a potential therapeutic agent targeting ISG20 for treating OC. In conclusion, we emphasize the significance of innate immunity in OC development and immunotherapy, and find ISG20 to be a prospective biomarker and therapeutic target.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • IFNA1 (Interferon Alpha 1) • IL1RN (Interleukin 1 receptor antagonist) • DYNLT1 (Dynein Light Chain Tctex-Type 1)
    over1year
    Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning. (PubMed, Front Immunol)
    Our study comprehensively elucidated the relationship between MASH and efferocytosis, constructing a favorable diagnostic model. Furthermore, we identified potential therapeutic targets for MASH treatment and offered novel insights into unraveling the underlying mechanisms of this disease.
    Journal • Machine learning
    |
    DYNLT1 (Dynein Light Chain Tctex-Type 1) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    2years
    The role of miR-223 in breast cancer; an integrated analysis. (PubMed, Mol Biol Rep)
    The results suggests that miR-223 and its targets, ANLN, DYNLT1, LRRC59, SLC12A8 and TPM3, might be reliable potential prognostic biomarkers in BRCA patients.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • TPM3 (Tropomyosin 3) • MIR223 (MicroRNA 223) • ANLN (Anillin Actin Binding Protein) • DYNLT1 (Dynein Light Chain Tctex-Type 1)
    over2years
    DYNLT1 promotes mitochondrial metabolism to fuel breast cancer development by inhibiting ubiquitination degradation of VDAC1. (PubMed, Mol Med)
    Our data demonstrate that DYNLT1 promotes mitochondrial metabolism to fuel breast cancer development by inhibiting Parkin-mediated ubiquitination degradation of VDAC1. This study suggests that mitochondrial metabolism can be exploited by targeting the DYNLT1-Parkin-VDAC1 axis to improve the ability of metabolic inhibitors to suppress cancers with limited treatment options, such as triple-negative breast cancer (TNBC).
    Journal
    |
    DYNLT1 (Dynein Light Chain Tctex-Type 1)